Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently ma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback